A Multicenter, Prospective, Randomized, Open-label, Blinded-endpoint, Phase 4 Study to Evaluate the Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With Chronic Chagas' Cardiomyopathy
Latest Information Update: 27 May 2025
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Enalapril
- Indications Chagas disease; Heart failure
- Focus Therapeutic Use
- Acronyms PARACHUTE-HF
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 18 Apr 2025 Status changed from active, no longer recruiting to completed.
- 14 Mar 2025 Planned End Date changed from 27 Feb 2025 to 31 Mar 2025.
- 14 Mar 2025 Planned primary completion date changed from 27 Feb 2025 to 28 Mar 2025.